Anemia News and Research

RSS
Anemia is a decrease in normal number of red blood cells (RBCs) or less than the normal quantity of hemoglobin in the blood. However, it can include decreased oxygen-binding ability of each hemoglobin molecule due to deformity or lack in numerical development as in some other types of hemoglobin deficiency. The three main classes of anemia include excessive blood loss (acutely such as a hemorrhage or chronically through low-volume loss), excessive blood cell destruction (hemolysis) or deficient red blood cell production (ineffective hematopoiesis). Anemia is the most common disorder of the blood. There are several kinds of anemia, produced by a variety of underlying causes. Anemia can be classified in a variety of ways, based on the morphology of RBCs, underlying etiologic mechanisms, and discernible clinical spectra, to mention a few.
ITM in Antwerp receives Gates Foundation grant for malaria research

ITM in Antwerp receives Gates Foundation grant for malaria research

FMCNA announces new educational resources to enhance RightStart

FMCNA announces new educational resources to enhance RightStart

Data from Alvine’s ALV003 Phase 2A trial on celiac disease presented at DDW 2012

Data from Alvine’s ALV003 Phase 2A trial on celiac disease presented at DDW 2012

ArQule to present positive tivantinib Phase 2 clinical data for hepatocellular carcinoma

ArQule to present positive tivantinib Phase 2 clinical data for hepatocellular carcinoma

Medgenics’ EPODURE receives FDA clearance to proceed into clinical trials

Medgenics’ EPODURE receives FDA clearance to proceed into clinical trials

Updated results from Amgen’s blinatumomab Phase 2 study on ALL

Updated results from Amgen’s blinatumomab Phase 2 study on ALL

Pfizer fails to meet primary endpoint in TORISEL Phase 3 study for advanced RCC

Pfizer fails to meet primary endpoint in TORISEL Phase 3 study for advanced RCC

Genetic cause of rare genetic disorder, Hamamy syndrome

Genetic cause of rare genetic disorder, Hamamy syndrome

Lenalidomide delays progression of multiple myeloma after stem cell transplant

Lenalidomide delays progression of multiple myeloma after stem cell transplant

Final results from Alnylam’s ALN-TTR01 Phase I trial on TTR-mediated amyloidosis

Final results from Alnylam’s ALN-TTR01 Phase I trial on TTR-mediated amyloidosis

Interim results from Seattle Genetics’ ADCETRIS phase II trial on CTCL

Interim results from Seattle Genetics’ ADCETRIS phase II trial on CTCL

NEJM publishes results from Celgene’s REVLIMID phase III studies on MM

NEJM publishes results from Celgene’s REVLIMID phase III studies on MM

Everett Labs announces availability of Pregnitude for women with fertility problems

Everett Labs announces availability of Pregnitude for women with fertility problems

Research identifies molecular trigger of fibroid uterine tumors

Research identifies molecular trigger of fibroid uterine tumors

Alnylam first quarter revenues decrease to $20.6 million

Alnylam first quarter revenues decrease to $20.6 million

Ligand first quarter total revenues increase to $5.6 million

Ligand first quarter total revenues increase to $5.6 million

FDA approves Protalix, Pfizer’s ELELYSO for treatment of type 1 Gaucher disease

FDA approves Protalix, Pfizer’s ELELYSO for treatment of type 1 Gaucher disease

Anlit Advanced Nutrition Supplements to present new products at Vitafoods Europe 2012

Anlit Advanced Nutrition Supplements to present new products at Vitafoods Europe 2012

DaVita first quarter net income increases to $140.1 million

DaVita first quarter net income increases to $140.1 million

Pfizer receives FDA approval for Elelyso to treat Type 1 Gaucher disease

Pfizer receives FDA approval for Elelyso to treat Type 1 Gaucher disease

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.